GlassScriptPhysician profile
Kevin Patrick Mcmullen
NPI 1093797045
$26,168.21
in general payments reported to CMS, 2019-2025
25 companies · $59.45 in 2025
The $59.45 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $285 · 2021: $15K · 2022: $10K · 2024: $24.12 · 2025: $59.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qt Imaging, INC. | $25,257.16 | 2020-2022 | |
| Amgen INC. | $135.19 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.89 | 2019-2020 | |
| Celgene Corporation | $65.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $63.25 | 2019 | |
| Clovis Oncology, INC. | $57.35 | 2019 | |
| Daiichi Sankyo INC. | $56.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $54.78 | 2019-2020 | |
| Eisai INC. | $54.02 | 2019 | |
| Novocure INC. | $47.64 | 2019-2024 | Optune |
| Janssen Biotech, INC. | $38.51 | 2019-2020 | |
| Teleflex LLC | $36.54 | 2025 | Barrigel |
| Portola Pharmaceuticals, LLC | $29.43 | 2019 | |
| Tersera Therapeutics LLC | $27.56 | 2019 | |
| Incyte Corporation | $23.17 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $22.91 | 2025 | Truebeam |
| Seagen INC. | $19.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.13 | 2019 | |
| Fortovia Therapeutics, INC. | $14.85 | 2019 | |
| Lilly USA, LLC | $14.51 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.38 | 2019 | |
| Puma Biotechnology, INC. | $12.92 | 2019 | |
| Gilead Sciences, INC. | $11.84 | 2019 | |
| Abbvie INC. | $11.50 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$209,863.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Mcmullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.